1471-2350-7-20 1471-2350 Research article <p>Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases</p> Smyth J Deborah debbie.smyth@cimr.cam.ac.uk Howson MM Joanna Joanna.Howson@cimr.cam.ac.uk Payne Felicity Fp1@sanger.ac.uk Maier M Lisa Lisa.Maier@cimr.cam.ac.uk Bailey Rebecca Rebecca.Bailey@cimr.cam.ac.uk Holland Kieran mail@kieranholland.com Lowe E Christopher Chris.Lowe@cimr.cam.ac.uk Cooper D Jason Jason.Cooper@cimr.cam.ac.uk Hulme S John John.Hulme@cimr.cam.ac.uk Vella Adrian vella.adrian@mayo.edu Dahlman Ingrid Ingrid.Dahlman@medhs.ki.se Lam C Alex A.C.H.Lam@sms.ed.ac.uk Nutland Sarah Sarah.Nutland@cimr.cam.ac.uk Walker M Neil Neil.Walker@cimr.cam.ac.uk Twells CJ Rebecca rebecca.twells@hinxton.wellcome.ac.uk Todd A John John.Todd@cimr.cam.ac.uk

Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke's Hospital, Hills Rd, Cambridge, CB2 2XY, UK

BMC Medical Genetics 1471-2350 2006 7 1 20 http://www.biomedcentral.com/1471-2350/7/20 16519819 10.1186/1471-2350-7-20
15 11 2005 06 3 2006 06 3 2006 2006 Smyth et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The identification of the HLA class II, insulin (INS), CTLA-4 and PTPN22 genes as determinants of type 1 diabetes (T1D) susceptibility indicates that fine tuning of the immune system is centrally involved in disease development. Some genes have been shown to affect several immune-mediated diseases. Therefore, we tested the hypothesis that alleles of susceptibility genes previously associated with other immune-mediated diseases might perturb immune homeostasis, and hence also associate with predisposition to T1D.

Methods

We resequenced and genotyped tag single nucleotide polymorphisms (SNPs) from two genes, CRP and FCER1B, and genotyped 27 disease-associated polymorphisms from thirteen gene regions, namely FCRL3, CFH, SLC9A3R1, PADI4, RUNX1, SPINK5, IL1RN, IL1RA, CARD15, IBD5-locus (including SLC22A4), LAG3, ADAM33 and NFKB1. These genes have been associated previously with susceptibility to a range of immune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Graves' disease (GD), psoriasis, psoriatic arthritis (PA), atopy, asthma, Crohn disease and multiple sclerosis (MS). Our T1D collections are divided into three sample subsets, consisting of set 1 families (up to 754 families), set 2 families (up to 743 families), and a case-control collection (ranging from 1,500 to 4,400 cases and 1,500 to 4,600 controls). Each SNP was genotyped in one or more of these subsets. Our study typically had approximately 80% statistical power for a minor allele frequency (MAF) >5% and odds ratios (OR) of 1.5 with the type 1 error rate, α = 0.05.

Results

We found no evidence of association with T1D at most of the loci studied 0.02 <P < 1.0. Only a SNP in ADAM33, rs2787094, was any evidence of association obtained, P = 0.0004 in set 1 families (relative risk (RR) = 0.78), but further support was not observed in the 4,326 cases and 4,610 controls, P = 0.57 (OR = 1.02).

Conclusion

Polymorphisms in a variety of genes previously associated with immune-mediated disease susceptibility and/or having effects on gene function and the immune system, are unlikely to be affecting T1D susceptibility in a major way, even though some of the genes tested encode proteins of immune pathways that are believed to be central to the development of T1D. We cannot, however, rule out effect sizes smaller than OR 1.5.

Background

The four susceptibility loci identified so far in T1D, the HLA class II gene complex 1, INS 2, CTLA4 3 and PTPN22 45 indicate that the regulation of T cell development, activation, expansion and homeostasis is a central component of disease development. A fifth locus, the IL2R2/CD25 region 6 awaits independent replication and fine mapping of the aetiological variant. With the exception of INS 7, these genes contain polymorphisms that are associated with susceptibility to other immune-mediated diseases.

Therefore, we hypothesised that further susceptibility variants for T1D may reside in genes previously associated with other immune-mediated diseases, as prior evidence suggests the presence of shared disease susceptibility genes. For example, in families with T1D, other immune-mediated diseases, such as RA and autoimmune thyroid disease (AITD), occur more frequently than expected by chance, indicative of a partly shared genetic basis 7. This model has gained significant support recently with the association of the Arg620Trp non-synonymous SNP in the PTPN22 gene, encoding the lymphoid specific phosphatase, LYP; not only with T1D 4 but also with GD, RA and SLE 589. Likewise CTLA4 has been associated with T1D, AITD, RA and SLE 310.

Furthermore, as susceptibility to T1D and other autoimmune diseases is probably directly related to the homeostatic, regulatory state of the immune system, it is possible that variants in immune response genes influence susceptibility to T1D via alteration of networks of immune regulation. For example, the CARD15 gene product, NOD2, influences the development of the adaptive immune response 1112 and functional variants of the gene predispose to the inflammatory bowel disease (IBD), Crohn disease (Table 1). Both the Th1 and mucosal immune system are thought to be important in T1D aetiology 13.

<p>Table 1</p>

Previously associated polymorphisms with other immune-mediated diseases and references.

Gene (locus link id)

Gene Function

Polymorphisms

MAF

Reference and previous association


CRP 1q21-q23 (1401)

Activates the classical pathway of complement. SNP2 alters basal levels of CRP. SNP4 has been associated with SLE and antinuclear autoantibody production. A polymorphic GT repeat in CRP has been associated with SLE.

SNP2 (rs1800947)

SNP4 (rs1205)

Microsatellite (ss28514831)

0.07 & 0.33 respectively, Caucasian parental. GT16 & GT21, 0.62 and 0.24, respectively, Caucasian controls.

SLE: Microsatellite P = 0.007, SNP4 P = 0.0008; 586 families [14].

Microsatellite [15].


FCRL3 1q21-q22 (115352)

FCRL3, a member of the Fc receptor-like family, polymorphism alters the binding affinity of nuclear factor κB and regulates FCRL3 expression. Associated with RA, SLE and autoimmune thyroid disease (GD and HT)

Fcrl3_3 (rs7528684)

0.37 Japanese controls

RA: P = 8.5 × 10-7, OR = 2.15 (95% CI = 1.58–2.93) 830 cases and 658 controls. SLE: P = 0.0017, OR = 1.49 (95% CI = 1.16–1.92) 564 cases. GD: P = 7.4 × 10-5, OR = 1.79 (95% CI = 1.34–2.39) 351 cases. HT: P = 0.022, OR = 1.62 (95% CI = 1.07–2.47) 158 cases [43].


CFH 1q32 (3075)

Complement factor H, a key regulator of the complement system of innate immunity, binds heparin and CRP

His402Tyr (rs1061170)

0.41 controls, white, not of Hispanic origin

Age-related macular degeneration: (nominal P = <10-7) 96 cases and 50 controls [44].


PAD14 1q36.13 (23569)

Peptidylarginine deiminases role in granulocyte & macrophage development, leading to inflammation and immune response, associated with RA.

PADI4-94 (rs2240340)

0.37 Japanese controls

RA: P = 8 × 10-6, OR = 1.97 (95% CI = 1.44–2.69) 830 cases and 736 controls [45].


IL1RN & IL1A 2q14 (3557 & 3552)

Cytokines involved in the inflammatory response, polymorphisms confer susceptibility to RA and Ankylosing spondylitis.

IL1RN+2017 (rs2419598)

IL1A-889 (rs1800587)

0.22 & 0.27, respectively, Caucasian controls

RA: P = 0.008; 406 Dutch cases and 245 controls [46].

Ankylosing spondylitis: P = 0.025; 227 British families, 317 parent-case trios and 200 controls [47].


NFKB1 4q24 (4790)

NFκB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NFκB has been associated with a number of inflammatory diseases

(CA) dinucleotide repeat microsatellite

Allele 8, A10 & A14, 0.19, 0.02 and 0.28 respectively, UK controls

T1D: A10: P = 0.000001, OR = 9.4; 434 cases, 222 controls [36]. T1D: no association; 236 Danish families [37].


SLC22A4 5q31 (6583)

The encoded protein is an organic cation transporter and plasma integral membrane protein containing eleven putative transmembrane domains as well as a nucleotide-binding site motif. Polymorphisms confer susceptibility to RA.

SLC22A4:F1 (rs2073838)

SLC22A4:F2 (rs3792876)

0.31 & 0.32 respectively, Japanese controls

RA: P = 0.000034, OR = 1.98 (95% CI = 1.43–2.75) 830 cases and 658 controls [48].

CD: P = 0.001, OR = 2.1 (95% CI = 1.31–3.39) 203 cases and 200 controls [49].


IBD5 locus 5q31 (50941)

Confers susceptibility to Crohn disease.

IGR2198 (rs11739135)

0.36 Canadian parental.

CD: P = 0.000048; 256 trios [50].


SPINK5 5q32 (11005)

Encodes a 15 domain serine proteinase inhibitor (LEKTI) involved in anti-inflammatory and/or antimicrobial protection of mucous epithelial, polymorphisms associated with atopy, Netherton disease.

316G>A (ss28514851)

1103A>G (rs2303064)

1156G>A (rs2303063)

1258G>A (rs2303067)

2475G>T (rs2303070)

2915A>G (ss28514856)

0.03, 0.50, 0.13, 0.48, 0.08 & 0.04, respectively, UK controls

Atopy, Netherton disease: (rs2303064): P = 0.008, (rs2303067): P = 0.002; 148 families [51].

Asthma (rs2303067): P = 0.04, OR = 1.77 (95% CI = 1.02–3.06) 1161 children. Asthma and atopy: P = 0.007, OR = 4.56 (95% CI = 1.37–15.12) 37 German cases and 415 controls [52].


FCER1B 11q13 (2206)

Encodes the beta subunit of the high affinity IgE receptor, a member of the membrane-spanning 4A gene family, and displays unique expression patterns among hematopoietic cells and nonlymphoid tissues. Responsible for initiating the allergic response, associated with atopy and atopic asthma.

Gly237Glu (rs569108)

0.06 Japanese controls

Atopy: two-point lod score 9.35 [17].

Childhood asthma (rs569108): P = <0.002, OR = 3; 200 Japanese cases and 100 controls [16].


LAG3 12p13.32 (3902)

Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains.

Thr455Ile (rs870849)

N/A

MS: P = 0.005; 576 cases and 662 controls [53].


CARD15 16q12 (64127)

Intracellular sensors of bacterial peptidoglycan These SNPs encode amino acid changes located in or near the leucine-rich repeat region, which is involved in peptidoglycan binding, conferring an increased risk of Crohn disease, PA and Blau syndrome.

SNP8 (rs2066844)

SNP12 (rs2066845)

SNP13 (ss28514842)

0.04, 0.01 & 0.02, respectively, Caucasian controls

CD (SNP13): P = 6 × 10-6; 235 families [54].

P = 0.0046; 416 families[55].

PA: P = 0.0027, OR = 3.5 (95% CI = 1.51–7.01) [56].

Blau Syndrome [57].


SLC9A3R1 17q25 (9368)

Immune synapse formation in T cells, polymorphism associated with psoriasis.

SLC9A3R1 (rs734232)

0.42 European controls

Psoriasis: P = 0.0009; 134 trios [58].


ADAM33 20p13 (80332)

Encodes a disintegrin and metalloprotease (ADAM) domain 33, which is a member of the ADAM protein family. Has a role in cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. Reported as an asthma and bronchial hyper-responsiveness susceptibility locus.

ST+4 (rs44707)

V4 (rs2787094)

Q-1 (rs612709)

ST+7 (rs574174)

T+1 (rs2280089)

T2 (rs2280090)

0.48, 0.25, 0.24, 0.22, 0.08, 0.07 UK & USA controls

Asthma and bronchial hyperresponsiveness: P = 0.03 – 0.02; 130 cases and 217 controls [35].

P = 0.04–0.0009 in ethnically diverse populations [59].


RUNX1 21q22.3 (861)

The RUNX1 transcription factor is expressed mainly in hematopoietic cells and functions both to activate and to repress transcription through interactions with cofactors. This SNP alters a binding site for RUNX1 and has been associated with RA.

RUNX1 (rs2268277)

0.37 Japanese controls

RA: P = 0.0013, OR= 1.28 (95% CI = 1.10–1.48) 719 cases and 441 controls [48].

MAF: minor allele frequency, SLE: systemic lupus erythematosus, RA: rheumatoid arthritis, GD: Graves' disease, HT: Hashimoto thyroiditis, T1D: type 1 diabetes, CD: Crohn disease, MS: multiple sclerosis, PA: Psoriatic arthritis, OR: odds ratio, 95% CI: 95% confidence intervals, N/A: not available

The aim of this study was to determine whether previously associated polymorphisms of immune-mediated disease also predispose to T1D. We genotyped a total of 41 polymorphisms, including three microsatellite markers, from 16 genes, shown in Table 1, in large T1D collections. For two genes C-reactive protein (CRP), a marker for inflammation and associated with susceptibility to SLE 1415, and FCER1B, high-affinity receptor for immunoglobulin E (IgE) (MS4A2), located in the putative T1D locus IDDM4, and associated with atopic illness 1617, we also carried out a re-sequencing effort, to gain a more comprehensive profile of allelic variation of the genes and their potential association with T1D. Our sample sizes had good statistical power for ORs greater than 1.5 (Additional File 1) 18.

<p>Additional File 1</p>

Power calculations for a range of allele frequencies.

Click here for file

Methods

Subjects

T1D families were white European or of white European descent, with two parents and at least one affected child comprising DNA samples from up to 476 multiplex Diabetes UK Warren 1families 19, 278 multiplex HBDI families 20, 250 simplex Northern Ireland families 21, 260 simplex Norwegian families and 233 simplex Romanian families with inclusion criteria as reported in Vella et al. 22. The T1D cases 23and the 1958 BBC controls 24 have been described previously 5. All DNA samples were collected after approval from the relevant research ethics committees and written informed consent was obtained from the participants. This project has run over a number of years during which samples of cases were still being collected. Consequently, owing to availability of DNA, polymorphisms were genotyped either in "set 1" families (n = 754 UK and USA multiplex families), "set 2" families (n = 743 Norwegian, Romanian and Northern Irish simplex families) and/or a British case-control collection consisting of between approximately 1,500 and 4,400 cases and 1,500 and 4,600 controls.

SNP identification and genotyping

CRP (EMBL Accession number AL445528) and FCER1B (AP001181) were annotated locally, importing Ensembl information into a temporary ACeDB database as described previously 25. After confirmation of gene structures by BLAST analysis, these were re-extracted in GFF format and submitted to T1Dbase 26.

Direct sequencing of nested PCR products from 32 T1D individuals was carried out for all exons of CRP and 3 kb 5' and 3' of the gene, using Applied Biosystems 3700 capillary sequencer. Polymorphisms were identified using the Staden Package and loaded into T1Dbase. FCER1B was also sequenced, as for CRP, in 96 T1D individuals for 2 kb 5' and 3 kb 3' of the gene and all exons, except exon 6, were successfully sequenced.

SNPs were genotyped using either TaqMan MGB chemistry (Applied Biosystems), Invader Biplex assay (Third Wave Technologies, Madison) 3 or PCR RFLP. The microsatellites were genotyped on an ABI3700 using fluorescent primers. All genotyping data were double scored to minimize error.

Family studies of variants with a MAF less than 5% may be compromised by apparent under transmission of alleles resulting from undetected genotyping errors 27. To evaluate potential genotyping errors we genotyped a large selection of samples from three SNPs: SNP8 (rs2066844), SNP12 (rs2066845), SNP13 (ss28514842), twice, using two different methods, either TaqMan, Invader or PCR RFLP. The concordance rate between the methods was >99.2%.

Statistical analyses

All statistical analyses were performed within STATA 28 making specific use of the Genassoc and htSNP2 packages for association and tag SNP selection, available from 29. All genotyping data of unaffected parents and controls were assessed for, and found to be in Hardy-Weinberg equilibrium (P > 0.05). Associations of the SNPs and microsatellites were tested by the Transmission/disequilibrium test in the families. Allelic and genotypic relative risks were calculated using pseudo-controls and cases with conditional logistic regression 30. In order to minimise any confounding due to variation in allele frequencies across Great Britain 31, case-control data were stratified by broad geographical region within the logistic regression model used to calculate ORs and test associations. Both genotypic and allelic effects were allowed for by modelling loci as three-level, 2 degrees of freedom (2 df), categorical variables corresponding to a model assuming no particular mode of inheritance and continuous (1 df) variables equating to a multiplicative model. Where a difference was found, by a likelihood ratio test, between the multiplicative model and a model assuming no particular mode of inheritance, the 2 df P-value is reported. The tag SNPs were analysed by use of a multivariate test statistic 632.

Results

For CRP and FCER1B, we resequenced and followed a tag selection approach, selecting tags that capture the variation of the remaining common SNPs (MAF ≥ 0.05) with a minimum R2 of 0.8 32. Nineteen SNPs were identified in CRP, five of which were novel (Additional File 2) 26 and seven tag SNPs were selected and genotyped in set 1 families (multilocus P = 0.49). We also genotyped the tag SNPs in the case-control collection (1,607 cases and 1,636 controls) and found no support for association (multilocus P = 0.42), indicating that common variants of CRP are unlikely to influence T1D susceptibility in a major way. The CRP intronic microsatellite (GT)n polymorphism (ss28514831) (Table 1 and Additional file 2) was also genotyped in set 1 and 2 families but showed no association with T1D (P = 0.90).

<p>Additional File 2</p>

Polymorphisms identified in CRP.

Click here for file

On resequencing FCER1B, which is located in the putative diabetes-susceptibility region IDDM4 33, we identified 34 SNPs, 17 of which were novel, and selected five tag SNPs (Additional File 3) 26. We were unable to detect the non-synonymous SNP in exon 7, Gly237Glu, in 96 DNA samples, that has previously been associated with atopic asthma 16. We initially genotyped the five tag SNPs in set 1 families (multilocus P = 0.085), and then followed this result up in set 2 families giving a combined multilocus P = 0.070 (adjusted for two-stage design). In 1,600 cases and 1,636 controls we obtained P = 0.24, and the combination of the multilocus family and case-control results indicated that variants of FCER1B are unlikely to play a major role in T1D susceptibility (P = 0.23). The FCER1B intronic microsatellite polymorphism (ss28514807) also showed no evidence of association with T1D in set 1 and 2 families (P = 0.65).

<p>Additional File 3</p>

Polymorphisms identified in FCER1B.

Click here for file

Five SNPs from FCRL3, CFH, SLC9A3R1, PADI4, RUNX1 and six SNPs from SPINK5 were genotyped in set 1 families and a minimum of 1,500 cases and 1,500 controls (Table 2). All except FCRL3 (TDT P = 0.04) and one locus in SPINK5 (P = 0.03), showed a P value of > 0.05. However, we did not obtain any further evidence of association of FCRL3 in 1,896 cases and 2,020 controls (Table 2). IL1RN, IL1RA, IGR2198 and the CARD15 SNPs 8, 12 and 13 were genotyped in sets 1 and 2 families, and all showed P > 0.10 (Table 3). The two SLC22A4 SNPs and the single LAG3 SNP were genotyped in a minimum of 3,290 cases and 3,549 controls and showed no evidence of association with T1D (Table 3).

<p>Table 2</p>

Association analyses in type 1 diabetes families and case-control sample sets for immune-mediated disease associated polymorphisms.

Published SNP

Set 1 families

Cases and controls


MAF

N parent-child trios (T/NT)

PTDT

Allelic RR [95% CI]

Genotype RR [95% CI]

MAF

N cases/controls

P1df

Allelic OR [95% CI]

Genotype OR [95% CI]


FCRL3 A>G rs7528684

0.46

901 (641/571)

0.04

0.89 [0.80–1.00]

A/A 1.00 [ref] A/G 0.88 [0.75–1.04] G/G 0.79 [0.63–1.00]

0.45

1896/2020

0.97

1.00 [0.91–1.10]

A/A 1.00 [ref] A/G 1.02 [0.87–1.18] G/G 0.99 [0.82–1.20]

CFH A>G rs1061170

0.38

823 (541/517)

0.46

0.96 [0.85–1.08]

A/A 1.00 [ref] A/G 1.00 [0.85–1.17] G/G 0.88 [0.68–1.14]

0.38

3149/3485

0.87

0.99 [0.92–1.07]

A/A 1.00 [ref] A/G 1.07 [0.96–1.19] G/G 0.94 [0.81–1.10]

SLC9A3R1 G>A rs734232

0.45

965 (644/642)

0.96

1.00 [0.90–1.12]

G/G 1.00 [ref] G/A 1.03 [0.88–1.21] A/A 1.00 [0.80–1.25]

0.45

1578/1736

0.34

1.05 [0.95–1.17]

G/G 1.00 [ref] G/A 0.92 [0.78–1.10] A/A 1.14 [0.92–1.41]

PADI4 C>T rs2240340

0.41

942 (610/655)

0.21

1.07 [0.96–1.20]

T/T 1.00 [ref] C/T 1.07 [0.92–1.25] C/C 1.15 [0.92–1.44]

0.42

1573/1732

0.87

1.01 [0.91–1.12]

T/T 1.00 [ref] C/T 1.09 [0.92–1.29] C/C 0.99 [0.80–1.23]

RUNX1 C>G rs2268277

0.34

896 (578/565)

0.70

1.02 [0.91–1.15]

T/T 1.00 [ref] T/C 0.96 [0.83–1.11] C/C 1.12 [0.87–1.43]

0.36

1586/1725

0.21

0.93 [0.84–1.04]

T/T 1.00 [ref] T/C 0.90 [0.76–1.05] C/C 0.90 [0.71–1.14]

SPINK5

+316 A>C ss28514851

0.04

178 (89/91)

0.88

0.98 [0.73–1.31]

A/A 1.00 [ref] A/C 0.98 [0.73–1.31] C/C 0.98 [0.10–9.55]

0.03

1540/1678

0.40

0.88 [0.66–1.18]

A/A 1.00 [ref] A/C 0.88 [0.65–1.19] C/C 0.82 [0.14–4.71]

+1103 T>C rs2303064

0.48

915 (583/602)

0.58

0.97 [0.86–1.09]

T/T 1.00 [ref] T/C 0.99 [0.84–1.17] C/C 0.94 [0.74–1.18]

0.47

1527/1665

0.30

0.95 [0.85–1.05]

T/T 1.00 [ref] T/C 0.96 [0.80–1.14] C/C 0.89 [0.72–1.10]

+1156 G>A rs2303063

0.10

357 (196/213)

0.40

0.92 [0.76–1.12]

G/G 1.00 [ref] G/A 0.93 [0.75–1.15] A/A 0.81 [0.42–1.57]

0.11

1530/1507

0.03 2 df

0.87 [0.73–1.04]

G/G 1.00 [ref] G/A 0.79 [0.64–0.96] A/A 1.48 [0.72–3.03]

+1258 C>T rs2303067

0.48

947 (617/622)

0.89

0.99 [0.89–1.11]

C/C 1.00 [ref] C/T 1.03 [0.87–1.22] T/T 0.98 [0.79–1.23]

0.47

1534/1641

0.36

0.95 [0.85–1.06]

C/C 1.00 [ref] C/T 0.98 [0.82–1.17] T/T 0.90 [0.73–1.12]

+2475 C>A rs2303070

0.07

317 (150/186)

0.05

0.81 [0.65–1.00]

C/C 1.00 [ref] C/A 0.85 [0.68–1.06] A/A 0.15 [0.02–1.13]

0.08

1479/1513

0.06 2 df

0.91 [0.73–1.12]

C/C 1.00 [ref] C/A 0.82 [0.66–1.04] A/A 2.51 [0.81–7.79]

+2915 A>G ss28514856

0.04

184 (92/105)

0.35

0.88 [0.66–1.16]

A/A 1.00 [ref] A/G 0.87 [0.65–1.17] G/G 0.82 [0.22–3.03]

0.03

1547/1685

0.91

0.98 [0.72–1.33]

A/A 1.00 [ref] A/G 0.98 [0.72–1.33] G/G -

MAF: Minor allele frequency, T: transmitted, NT: not transmitted, TDT: transmission/disequilibrium test P value, RR: relative risk, 95% CI: 95% confidence intervals, OR: odds ratio N: number.

<p>Table 3</p>

Association analyses in type 1 diabetes families and case-control sample sets for rheumatoid arthritis, inflammatory bowl disease and multiple sclerosis associated polymorphisms.

Published SNP

Set 1 and 2 families

Cases and controls


MAF

N parent-child trios (T/NT)

PTDT

Allelic RR [95% CI]

Genotype RR [95% CI]

MAF

N Cases/controls

P1df

Allelic OR [95%CI]

Genotype OR [95%CI]


IL1RN +2017 T>C rs2419598

0.28

1418 (916/865)

0.23

1.06 [0.96–1.16]

T/T 1.00 [ref] T/C 1.12 [0.99–1.25] C/C 1.03 [0.83–1.28]

n/a

n/a

n/a

n/a

n/a

IL1RA -889 C>T rs1800587

0.30

1431 (925/913)

0.78

1.01 [0.92–1.11]

C/C 1.00 [ref] C/T 1.02 [0.91–1.15] T/T 1.02 [0.83–1.25]

n/a

n/a

n/a

n/a

n/a

CARD15

SNP8 +2023C>T rs2066844

0.03

252 (123/143)

0.22

0.86 [0.68–1.09]

C/C 1.00 [ref] C/T 0.90 [0.70–1.15] T/T 0.22 [0.03–1.66]

n/a

n/a

n/a

n/a

n/a

SNP12 +3641G>C rs2066845

0.01

127 (57/72)

0.19

0.79 [0.56–1.12]

G/G 1.00 [ref] G/C 0.81 [0.57–1.14] C/C -

n/a

n/a

n/a

n/a

n/a

SNP13 +2936insC ss28514842

0.01

143 (73/72)

0.93

1.01 [0.73–1.40]

1/1 1.00 [ref] 1/2 1.00 [0.72–1.38] 2/2 2.99 [0.19–48.22]

n/a

n/a

n/a

n/a

n/a

IGR2198 G>C rs11739135

0.40

1511 (988/1008)

0.65

0.98 [0.90–1.07]

G/G 1.00 [ref] G/C 0.95 [0.84–1.07] C/C 0.98 [0.82–1.17]

n/a

n/a

n/a

n/a

n/a

SLC22A4 G>A rs3792876

n/a

n/a

n/a

n/a

n/a

0.08

3303/3558

0.93

0.99 [0.87–1.14]

C/C 1.0 [ref] C/T 1.01 [0.87–1.16] T/T 0.83 [0.40–1.70]

SLC22A4 C>T rs2073838

n/a

n/a

n/a

n/a

n/a

0.08

3290/3549

0.79

0.98 [0.86–1.12]

G/G 1.00 [ref] G/A 1.00 [0.87–1.15] A/A 0.74 [0.36–1.52]

LAG3 G>A rs870849

n/a

n/a

n/a

n/a

n/a

0.36

3860/4297

0.90

1.00 [0.93–1.06]

G/G 1.00 [ref] G/A 1.00 [0.91–1.10] A/A 0.99 [0.86–1.14]

MAF: Minor allele frequency, T: transmitted, NT: not transmitted, TDT: transmission/disequilibrium test P value, RR: relative risk, 95% CI: 95% confidence intervals, OR: odds ratio, N: number, n/a: not attempted

As a potential atopy/asthma susceptibility locus, ADAM33 was considered as a candidate gene for T1D because atopic illness and T1D have been inversely associated 34. No functional candidate SNPs in ADAM33 have been identified, but it is plausible that the SNPs in introns or the 3' region are located in regulatory sequences and thus may affect transcriptional efficiency or transcript stability 35. We genotyped six SNPs that showed a P ≤ 0.03 in asthma case-control data 35 in set 1 families (Tables 1 and 4). One SNP, ADAM33 V4 (rs2787094), showed P = 0.0004 (RR = 0.78, 95% CI = 0.67–0.89) initially in 754 families, and P = 4.4 × 10-6 (RR = 0.77, 95% CI = 0.69–0.86) when genotyped in the additional set 2 families. However, we did not obtain additional support for association in 4,326 cases and 4,610 controls (P = 0.57) (Table 4).

<p>Table 4</p>

Association analyses in type 1 diabetes families and case-control sample sets for ADAM33 SNPs

Published SNP

Set 1 families

Cases and controls


MAF

N parent-child trios (T/NT)

PTDT

Allelic RR [95% CI]

Genotype RR [95% CI]

MAF

N cases/controls

P1df

Allelic OR [95%CI]

Genotype OR [95%CI]


ST+4 rs44707

0.39

703 (421/443)

0.02*

0.95 [0.83–1.09]

C/C 1.00 [ref] A/C 0.80 [0.67–0.96] A/A 0.99 [0.76–1.30]

n/a

n/a

n/a

n/a

n/a

**V4 rs2787094

0.23

653 (350/451)

0.0004

0.78 [0.67–0.89]

G/G 1.00 [ref] G/C 0.78 [0.67–0.92] C/C 0.59 [0.41–0.85]

0.22

4326/4610

0.57

1.02 [0.95–1.10]

G/G 1.00 [ref] G/C 1.04 [0.95–1.14] C/C 0.99 [0.81–1.22]

Q-1 rs612709

0.14

402 (219/247)

0.02*

0.89 [0.74–1.06]

G/G 1.00 [ref] G/A 0.99 [0.81–1.21] A/A 0.42 [0.22–0.83]

n/a

n/a

n/a

n/a

n/a

ST+7 rs574174

0.20

669 (392/393)

0.97

1.00 [0.87–1.15]

T/T 1.00 [ref] T/C 1.02 [0.87–1.20] C/C 0.92 [0.63–1.34]

n/a

n/a

n/a

n/a

n/a

T+1 rs2280089

0.13

512 (274/304)

0.21

0.90 [0.77–1.06]

G/G 1.00 [ref] C/G 0.90 [0.75–1.07] C/C 0.83 [0.49–1.43]

n/a

n/a

n/a

n/a

n/a

T2 rs2280090

0.13

520 (277/314)

0.13

0.88 [0.75–1.04]

T/T 1.00 [ref] T/C 0.88 [0.73–1.05] C/C 0.81 [0.47–1.39]

n/a

n/a

n/a

n/a

n/a

MAF: minor allele frequency. T: transmitted. NT: not transmitted. TDT: transmission/disequilibrium test. P value. RR: relative risk. 95% CI: 95% confidence intervals. OR: odd ratios. N: number. n/a: not attempted.

* Two degree of freedom GTRR (genotype relative risk) P value is reported as its significantly different to the TDT P value.

** In set 1 and 2 families (1075(571/737) parent-child trios) for ADAM33 V4, PTDT = 4.43 × 10-6, with allelic RR = 0.77 [0.69–0.86] and genotype relative risks: G/G 1.00 [ref], G/C 0.80 [0.70–0.91], C/C 0.54 [0.40–0.73].

Finally, we genotyped the NFKB1 dinucleotide repeat (CA) microsatellite polymorphism, which has been associated with T1D 36, albeit inconsistently 37 (Table 1). In our set 1 families, we failed to find any evidence for an association with T1D (P = 0.68).

Discussion

Co-localization and overlapping of genetic loci in autoimmune diseases suggests that in some cases, common biological pathways may be involved in the aetiology of T1D and other clinically distinct immune-mediated diseases. In this study we examined 16 genes implicated in autoimmune and other immune-mediated diseases and report that none of the variants tested, consistently showed P values of less than 0.05 in association tests with T1D. Our data indicate that, although common immune-mediated disease loci are present in the genome, there are disease genes that are distinct to certain diseases. Indeed, the known T1D susceptibility loci follow this observation: while both CTLA4 and PTPN22 loci are associated with several autoimmune diseases 338, the insulin VNTR locus is likely to be T1D-specific rather than a general autoimmune locus 7.

Conclusion

The possibility remains that some of the investigated genes and variants are associated with T1D, albeit with weak genetic effects, such as with ORs of less than 1.3, for which the sample size employed in our study does not provide sufficient statistical power. Even a case-control sample of 8,000 cases and 8,000 controls would only have 48% statistical power at a type 1 error rate α of 0.001 for a disease variant with a MAF of 0.10 and OR of 1.15. As genotyping costs decrease, it will be necessary to test the variants in larger sample sets than reported here, because the identification of genetic effects with ORs in the 1.15–1.25 range can be instrumental in the understanding of the disease process of T1D 3. For example, we note that an observed genetic effect of OR 1.15, such as that exerted by the T1D susceptibility locus CTLA4, does not reflect the importance of the biological effect contributed by the locus through the protein(s) it encodes and the pathways it regulates 3.

Lack of association with variants tested here may also be partly due to false positive results obtained in the reported primary disease association studies. As shown in Table 1, these generally employed small sample sets, which is a common explanation in the reporting of P values that cannot be replicated in independent studies using larger sample sizes 39404142. Nevertheless, for ORs >1.5 our present study had good statistical power even for alleles at 0.01 frequency.

Abbreviations

T1D-type 1 diabetes, SNPs-single nucleotide polymorphisms, MAF-minor allele frequency, OR-odds ratio, RR-relative risk, RA-rheumatoid arthritis, SLE-systemic lupus erythemastosus, GD-Graves' disease, PA-psoriatic arthritis, MS-multiple sclerosis.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

DJS performed sequencing, SNP genotyping, data analysis and drafted the manuscript. JMMH performed statistical analysis and drafted the manuscript. FP performed sequencing, SNP genotyping and data analysis. LMM performed sequencing, SNP genotyping, data analysis and drafted the manuscript. JDC performed statistical analysis. KH & CL performed sequencing and SNP genotyping. JH, RB, AV & ID performed SNP genotyping and data analysis.

ACL coordinated annotation of genes. SN prepared DNA samples. NMW managed the data. RCJT coordinated the study. JAT participated in the conception, design and coordination of the study and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank the Juvenile Diabetes Research Foundation, the Wellcome Trust, Diabetes UK and the Medical Research Council, for financial support. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. We gratefully acknowledge the participation of all patients, controls and family members.

Thanks to Helen Stevens, Gillian Coleman, Sarah Field, Trupti Mistry, Sally Clayton, Matthew Hardy, Pamela Lauder, Meeta Maisuria, William Meadows and Sarah Wood for preparing DNA samples. We acknowledge use of DNA collections from Cristian Guja (Romania), Kjersti Ronningen and Dag Undlien (Norway), David Savage, Chris Patterson and Peter Maxwell (Northern Ireland), David Dunger and Barry Widmer (JDRF/WT Diabetes and Inflammation Laboratory UK GRID Cases) and David Strachan (1958 British Birth Cohort controls). Adrian Vella is a Mayo Foundation scholar, and Kieran Holland received financial support from the Royal College of Pathologists of Australasia.

<p>A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins</p> Cucca F Lampis R Congia M Angius E Nutland S Bain SC Barnett AH Todd JA Hum Mol Genet 2001 10 2025 2037 10.1093/hmg/10.19.2025 11590120 <p>Remapping the insulin gene <it>IDDM2 </it>locus in type 1 diabetes</p> Barratt BJ Payne F Lowe CE Hermann R Healy BC Harold D Concannon P Gharani N McCarthy MI Olavesen MG McCormack R Guja C Ionescu-Tirgoviste C Undlien DE Ronningen KS Gillespie KM Tuomilehto-Wolf E Tuomilehto J Bennett ST Clayton DG Cordell HJ Todd JA Diabetes 2004 53 1884 1889 15220214 <p>Association of the T-cell regulatory gene <it>CTLA4 </it>with susceptibility to autoimmune disease</p> Ueda H Howson JM Esposito L Heward J Snook H Chamberlain G Rainbow DB Hunter KM Smith AN Di Genova G Herr MH Dahlman I Payne F Smyth D Lowe C Twells RC Howlett S Healy B Nutland S Rance HE Everett V Smink LJ Lam AC Cordell HJ Walker NM Bordin C Hulme J Motzo C Cucca F Hess JF Metzker ML Rogers J Gregory S Allahabadia A Nithiyananthan R Tuomilehto-Wolf E Tuomilehto J Bingley P Gillespie KM Undlien DE Ronningen KS Guja C Ionescu-Tirgoviste C Savage DA Maxwell AP Carson DJ Patterson CC Franklyn JA Clayton DG Peterson LB Wicker LS Todd JA Gough SC Nature 2003 423 506 511 10.1038/nature01621 12724780 <p>A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes</p> Bottini N Musumeci L Alonso A Rahmouni S Nika K Rostamkhani M MacMurray J Meloni GF Lucarelli P Pellecchia M Eisenbarth GS Comings D Mustelin T Nat Genet 2004 36 337 338 10.1038/ng1323 15004560 <p>Replication of an Association Between the Lymphoid Tyrosine Phosphatase Locus (<it>LYP/PTPN22</it>) With Type 1 Diabetes, and Evidence for Its Role as a General Autoimmunity Locus</p> Smyth D Cooper JD Collins JE Heward JM Franklyn JA Howson JM Vella A Nutland S Rance HE Maier L Barratt BJ Guja C Ionescu-Tirgoviste C Savage DA Dunger DB Widmer B Strachan DP Ring SM Walker N Clayton DG Twells RC Gough SC Todd JA Diabetes 2004 53 3020 3023 15504986 <p>Localization of a type 1 diabetes locus in the <it>IL2RA/CD25 </it>region by use of tag single-nucleotide polymorphisms</p> Vella A Cooper JD Lowe CE Walker N Nutland S Widmer B Jones R Ring SM McArdle W Pembrey ME Strachan DP Dunger DB Twells RC Clayton DG Todd JA Am J Hum Genet 2005 76 773 779 1199367 15776395 10.1086/429843 <p>Evidence for a Type 1 diabetes-specific mechanism for the insulin gene-associated <it>IDDM2 </it>locus rather than a general influence on autoimmunity</p> Tait KF Collins JE Heward JM Eaves I Snook H Franklyn JA Barnett AH Todd JA Maranian M Compston A Sawcer S Gough SC Diabet Med 2004 21 267 270 10.1111/j.1464-5491.2004.01129.x 15008838 <p>A Missense Single-Nucleotide Polymorphism in a Gene Encoding a Protein Tyrosine Phosphatase (<it>PTPN22</it>) Is Associated with Rheumatoid Arthritis</p> Begovich AB Carlton VE Honigberg LA Schrodi SJ Chokkalingam AP Alexander HC Ardlie KG Huang Q Smith AM Spoerke JM Conn MT Chang M Chang SY Saiki RK Catanese JJ Leong DU Garcia VE McAllister LB Jeffery DA Lee AT Batliwalla F Remmers E Criswell LA Seldin MF Kastner DL Amos CI Sninsky JJ Gregersen PK Am J Hum Genet 2004 75 <p>Genetic Association of the R620W Polymorphismof Protein Tyrosine Phosphatase <it>PTPN22 </it>with Human SLE</p> Kyogoku C Langefeld CD Ortmann WA Lee A Selby S Carlton VE Chang M Ramos P Baechler EC Batliwalla FM Novitzke J Williams AH Gillett C Rodine P Graham RR Ardlie KG Gaffney PM Moser KL Petri M Begovich AB Gregersen PK Behrens TW Am J Hum Genet 2004 75 504 507 1182029 15273934 10.1086/423790 <p>CTLA-4 in autoimmune diseases – a general susceptibility gene to autoimmunity?</p> Kristiansen OP Larsen ZM Pociot F Genes Immun 2000 1 170 184 10.1038/sj.gene.6363655 11196709 <p><it>NOD2 </it>is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses</p> Watanabe T Kitani A Murray PJ Strober W Nat Immunol 2004 5 800 808 10.1038/ni1092 15220916 <p>Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract</p> Kobayashi KS Chamaillard M Ogura Y Henegariu O Inohara N Nunez G Flavell RA Science 2005 307 731 734 10.1126/science.1104911 15692051 <p>Cow's milk and type 1 diabetes: the real debate is about mucosal immune function</p> Harrison LC Honeyman MC Diabetes 1999 48 1501 1507 10426365 <p>Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus</p> Russell AI Cunninghame Graham DS Shepherd C Roberton CA Whittaker J Meeks J Powell RJ Isenberg DA Walport MJ Vyse TJ Hum Mol Genet 2004 13 137 147 10.1093/hmg/ddh021 14645206 <p>Association between baseline levels of C-reactive protein (<it>CRP</it>) and a dinucleotide repeat polymorphism in the intron of the CRP gene</p> Szalai AJ McCrory MA Cooper GS Wu J Kimberly RP Genes Immun 2002 3 14 19 10.1038/sj.gene.6363820 11857055 <p>Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population</p> Shirakawa T Mao XQ Sasaki S Enomoto T Kawai M Morimoto K Hopkin J Hum Mol Genet 1996 5 2068 10.1093/hmg/5.8.1129 8968765 <p>Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor</p> Shirakawa T Li A Dubowitz M Dekker JW Shaw AE Faux JA Ra C Cookson WO Hopkin JM Nat Genet 1994 7 125 129 10.1038/ng0694-125 7920628 <p>A note on power approximations for the transmission/disequilibrium test</p> Knapp M Am J Hum Genet 1999 64 1177 1185 1377842 10090903 <p>The British Diabetic Association – Warren repository</p> Bain SC Todd JA Barnett AH Autoimmunity 1990 7 83 85 2151758 <p>Family cell lines available for research</p> Lernmark A Ducat L Eisenbarth G Ott J Permutt MA Rubenstein P Spielman R Am J Hum Genet 1990 47 1028 1030 2239968 <p>Epidemiology of childhood IDDM in Northern Ireland 1989–1994: low incidence in areas with highest population density and most household crowding. Northern Ireland Diabetes Study Group</p> Patterson CC Carson DJ Hadden DR Diabetologia 1996 39 1063 1069 8877290 <p>Lack of association of the Ala(45)Thr polymorphism and other common variants of the NeuroD gene with type 1 diabetes</p> Vella A Howson JM Barratt BJ Twells RC Rance HE Nutland S Tuomilehto-Wolf E Tuomilehto J Undlien DE Ronningen KS Guja C Ionescu-Tirgoviste C Savage DA Todd JA Diabetes 2004 53 1158 1161 15047635 <p>T1D Cases</p> http://www-gene.cimr.cam.ac.uk/ucdr/grid.shtml <p>1958 Controls</p> http://www.cls.ioe.ac.uk/studies.asp?section=000100020003 <p>Development of an integrated genome informatics, data management and workflow infrastructure: a toolbox for the study of complex disease genetics</p> Burren OS Healy BC Lam AC Schuilenburg H Dolman GE Everett VH Laneri D Nutland S Rance HE Payne F Smyth D Lowe C Barratt BJ Twells RC Rainbow DB Wicker LS Todd JA Walker NM Smink LJ Hum Genomics 2004 1 98 109 15601538 <p>T1DBase</p> http://T1DBase.org <p>Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test</p> Mitchell AA Cutler DJ Chakravarti A Am J Hum Genet 2003 72 598 610 1180236 12587097 10.1086/368203 <p>STATA</p> http://www.stata.com <p>software</p> http://www-gene.cimr.cam.ac.uk/clayton/software/stata <p>A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes</p> Cordell HJ Clayton DG Am J Hum Genet 2002 70 124 141 384883 11719900 10.1086/338007 <p>Population structure, differential bias and genomic control in a large-scale, case-control association study</p> Clayton DG Walker NM Smyth DJ Pask R Cooper JD Maier LM Smink LJ Lam AC Ovington NR Stevens HE Nutland S Howson JM Faham M Moorhead M Jones HB Falkowski M Hardenbol P Willis TD Todd JA Nat Genet 2005 37 1243 1246 10.1038/ng1653 16228001 <p>Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power</p> Chapman JM Cooper JD Todd JA Clayton DG Hum Hered 2003 56 18 31 10.1159/000073729 14614235 <p>Fine mapping of the diabetes-susceptibility locus, <it>IDDM4</it>, on chromosome 11q13</p> Nakagawa Y Kawaguchi Y Twells RC Muxworthy C Hunter KM Wilson A Merriman ME Cox RD Merriman T Cucca F McKinney PA Shield JP Tuomilehto J Tuomilehto-Wolf E Ionesco-Tirgoviste C Nistico L Buzzetti R Pozzilli P Joner G Thorsby E Undlien DE Pociot F Nerup J Ronningen KS Todd JA Am J Hum Genet 1998 63 547 556 10.1086/301974 9683605 1377315 <p>A meta-analysis of the association between childhood type 1 diabetes and atopic disease</p> Cardwell CR Shields MD Carson DJ Patterson CC Diabetes Care 2003 26 2568 2574 12941720 <p>Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness</p> Van Eerdewegh P Little RD Dupuis J Del Mastro RG Falls K Simon J Torrey D Pandit S McKenny J Braunschweiger K Walsh A Liu Z Hayward B Folz C Manning SP Bawa A Saracino L Thackston M Benchekroun Y Capparell N Wang M Adair R Feng Y Dubois J FitzGerald MG Huang H Gibson R Allen KM Pedan A Danzig MR Umland SP Egan RW Cuss FM Rorke S Clough JB Holloway JW Holgate ST Keith TP Nature 2002 418 426 430 10.1038/nature00878 12110844 <p>NFkappaB polymorphisms and susceptibility to type 1 diabetes</p> Hegazy DM O'Reilly DA Yang BM Hodgkinson AD Millward BA Demaine AG Genes Immun 2001 2 304 308 10.1038/sj.gene.6363776 11607785 <p>Characterization of a nuclear-factor-kappa B (NFkappaB) genetic marker in type 1 diabetes (T1DM) families</p> Gylvin T Bergholdt R Nerup J Pociot F Genes Immun 2002 3 430 432 10.1038/sj.gene.6363916 12424626 <p>Genetic susceptibility to type 1 diabetes</p> Maier LM Wicker LS Curr Opin Immunol 2005 17 601 608 10.1016/j.coi.2005.09.013 16226440 <p>Genome-wide association studies: theoretical and practical concerns</p> Wang WY Barratt BJ Clayton DG Todd JA Nat Rev Genet 2005 6 109 118 10.1038/nrg1522 15716907 <p>Parameters for reliable results in genetic association studies in common disease</p> Dahlman I Eaves IA Kosoy R Morrison VA Heward J Gough SC Allahabadia A Franklyn JA Tuomilehto J Tuomilehto-Wolf E Cucca F Guja C Ionescu-Tirgoviste C Stevens H Carr P Nutland S McKinney P Shield JP Wang W Cordell HJ Walker N Todd JA Concannon P Nat Genet 2002 30 149 150 10.1038/ng825 11799396 <p>Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease</p> Lohmueller KE Pearce CL Pike M Lander ES Hirschhorn JN Nat Genet 2003 33 177 182 10.1038/ng1071 12524541 <p>Genetic associations in large versus small studies: an empirical assessment</p> Ioannidis JP Trikalinos TA Ntzani EE Contopoulos-Ioannidis DG Lancet 2003 361 567 571 10.1016/S0140-6736(03)12516-0 12598142 <p>A functional variant in <it>FCRL3</it>, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities</p> Kochi Y Yamada R Suzuki A Harley JB Shirasawa S Sawada T Bae SC Tokuhiro S Chang X Sekine A Takahashi A Tsunoda T Ohnishi Y Kaufman KM Kang CP Kang C Otsubo S Yumura W Mimori A Koike T Nakamura Y Sasazuki T Yamamoto K Nat Genet 2005 37 478 485 1362949 15838509 10.1038/ng1540 <p>Complement factor H polymorphism in age-related macular degeneration</p> Klein RJ Zeiss C Chew EY Tsai JY Sackler RS Haynes C Henning AK Sangiovanni JP Mane SM Mayne ST Bracken MB Ferris FL Ott J Barnstable C Hoh J Science 2005 308 385 389 10.1126/science.1109557 15761122 <p>Functional haplotypes of <it>PADI4</it>, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis</p> Suzuki A Yamada R Chang X Tokuhiro S Sawada T Suzuki M Nagasaki M Nakayama-Hamada M Kawaida R Ono M Ohtsuki M Furukawa H Yoshino S Yukioka M Tohma S Matsubara T Wakitani S Teshima R Nishioka Y Sekine A Iida A Takahashi A Tsunoda T Nakamura Y Yamamoto K Nat Genet 2003 34 395 402 10.1038/ng1206 12833157 <p>Relationship of polymorphisms of the Interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis</p> Kaijzel EL van Dongen H Bakker AM Breedveld FC Huizinga TW Verweij CL Tissue Antigens 2002 59 122 126 10.1034/j.1399-0039.2002.590208.x 12028539 <p>The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis</p> Timms AE Crane AM Sims AM Cordell HJ Bradbury LA Abbott A Coyne MR Beynon O Herzberg I Duff GW Calin A Cardon LR Wordsworth BP Brown MA Am J Hum Genet 2004 75 587 595 1182046 15309690 10.1086/424695 <p>An intronic SNP in a <it>RUNX1 </it>binding site of <it>SLC22A4</it>, encoding an organic cation transporter, is associated with rheumatoid arthritis</p> Tokuhiro S Yamada R Chang X Suzuki A Kochi Y Sawada T Suzuki M Nagasaki M Ohtsuki M Ono M Furukawa H Nagashima M Yoshino S Mabuchi A Sekine A Saito S Takahashi A Tsunoda T Nakamura Y Yamamoto K Nat Genet 2003 35 341 348 10.1038/ng1267 14608356 <p>Functional variants of <it>OCTN </it>cation transporter genes are associated with Crohn disease</p> Peltekova VD Wintle RF Rubin LA Amos CI Huang Q Gu X Newman B Van Oene M Cescon D Greenberg G Griffiths AM St George-Hyslop PH Siminovitch KA Nat Genet 2004 36 471 475 10.1038/ng1339 15107849 <p>Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease</p> Rioux JD Daly MJ Silverberg MS Lindblad K Steinhart H Cohen Z Delmonte T Kocher K Miller K Guschwan S Kulbokas EJ O'Leary S Winchester E Dewar K Green T Stone V Chow C Cohen A Langelier D Lapointe G Gaudet D Faith J Branco N Bull SB McLeod RS Griffiths AM Bitton A Greenberg GR Lander ES Siminovitch KA Hudson TJ Nat Genet 2001 29 223 228 10.1038/ng1001-223 11586304 <p>Gene polymorphism in Netherton and common atopic disease</p> Walley AJ Chavanas S Moffatt MF Esnouf RM Ubhi B Lawrence R Wong K Abecasis GR Jones EY Harper JI Hovnanian A Cookson WO Nat Genet 2001 29 175 178 10.1038/ng728 11544479 <p>Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample</p> Kabesch M Carr D Weiland SK von Mutius E Clin Exp Allergy 2004 34 340 345 10.1111/j.1365-2222.2004.01860.x 15005725 <p>Two genes encoding immune-regulatory molecules (<it>LAG3 </it>and <it>IL7R</it>) confer susceptibility to multiple sclerosis</p> Zhang Z Duvefelt K Svensson F Masterman T Jonasdottir G Salter H Emahazion T Hellgren D Falk G Olsson T Hillert J Anvret M Genes Immun 2005 6 145 152 10.1038/sj.gene.6364171 15674389 <p>Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease</p> Hugot JP Chamaillard M Zouali H Lesage S Cezard JP Belaiche J Almer S Tysk C O'Morain CA Gassull M Binder V Finkel Y Cortot A Modigliani R Laurent-Puig P Gower-Rousseau C Macry J Colombel JF Sahbatou M Thomas G Nature 2001 411 599 603 10.1038/35079107 11385576 <p>A frameshift mutation in <it>NOD2 </it>associated with susceptibility to Crohn's disease</p> Ogura Y Bonen DK Inohara N Nicolae DL Chen FF Ramos R Britton H Moran T Karaliuskas R Duerr RH Achkar JP Brant SR Bayless TM Kirschner BS Hanauer SB Nunez G Cho JH Nature 2001 411 603 606 10.1038/35079114 11385577 <p><it>CARD15</it>: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis</p> Rahman P Bartlett S Siannis F Pellett FJ Farewell VT Peddle L Schentag CT Alderdice CA Hamilton S Khraishi M Tobin Y Hefferton D Gladman DD Am J Hum Genet 2003 73 677 681 1180694 12879366 10.1086/378076 <p><it>CARD15 </it>mutations in Blau syndrome</p> Miceli-Richard C Lesage S Rybojad M Prieur AM Manouvrier-Hanu S Hafner R Chamaillard M Zouali H Thomas G Hugot JP Nat Genet 2001 29 19 20 10.1038/ng720 11528384 <p>A putative <it>RUNX1 </it>binding site variant between <it>SLC9A3R1 </it>and <it>NAT9 </it>is associated with susceptibility to psoriasis</p> Helms C Cao L Krueger JG Wijsman EM Chamian F Gordon D Heffernan M Daw JA Robarge J Ott J Kwok PY Menter A Bowcock AM Nat Genet 2003 35 349 356 10.1038/ng1268 14608357 <p>Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations</p> Howard TD Postma DS Jongepier H Moore WC Koppelman GH Zheng SL Xu J Bleecker ER Meyers DA J Allergy Clin Immunol 2003 112 717 722 10.1016/S0091-6749(03)01939-0 14564349

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/7/20/prepub